China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within its corporate structure. The company’s sub-subsidiary, China Resources Kunming Shenghuo Pharmaceutical CO., Ltd., also known as CR Sanjiu (SHE: 000999), is poised to sell its 51% stake in Shenghuo to another subsidiary of CR Pharma, KPC Pharmaceuticals Inc., (SHA: 600422), in a deal valued at RMB 1.791 billion (USD 247 million).
Stake Sale and Financial Allocation
The sale of the 51% stake in Shenghuo to KPC Pharmaceuticals is part of a strategic move to optimize CR Pharma’s asset allocation and operational efficiency. The proceeds from this transaction are intended to be used as supplementary working capital, which will support the company’s ongoing operations and financial flexibility.
Impact on CR Sanjiu and KPC Pharmaceuticals
This internal restructuring is expected to streamline the business operations of both CR Sanjiu and KPC Pharmaceuticals, potentially leading to enhanced performance and growth. By consolidating stakes and reallocating resources, CR Pharma is positioning itself for a stronger presence in the pharmaceutical market.-Fineline Info & Tech
Leave a Reply